ClinicalTrials.gg
RecruitingNCT07577583Updated Oct 29, 2026

Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel

An observational study in B-cell Mediated Autoimmune Disorders, sponsored by TG Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 62 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by TG Therapeutics, Inc. · Observational

How we know

Updated Oct 29, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
32
Ages
18 Years to 62 Years
Sex
All
01

Study summary

The main objective of this study is to collect data on the long-term safety of azer-cel, primarily through the capture of clinical events of interest (CEI) for up to 15 years following participation in TG-Azercel -101 study.

02

Conditions studied

  • B-cell Mediated Autoimmune Disorders
03

In context

Lead sponsor

TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 62 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any participants receiving azer-cel in TG-Azercel -101 study will be enrolled in this LTFU study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Received at least 1 dose of azer-cel in TG-Azercel -101 study.
  2. Signed form (ICF).
  3. Willingness and ability to adhere to the study schedule and all other protocol requirements.

Exclusion criteria

Exclusion Citeria:

1. No unique exclusion criteria apply to this study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
32 participants (estimated)
Target follow-up
15 Years
Patient registry
Yes

Groups and cohorts

  • Long-term Follow-up

    Participants who received azer-cel in TG-Azercel -101 study will be followed-up for a total of 15 years until withdrawal of consent, lost to follow-up, or until death.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    No Intervention

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinically Significant CEI

    Time frame: Up to 15 years

  2. Number of Participants With Clinically Significant CEI Based on Severity

    Time frame: Up to 15 years

  3. Duration of Clinically Significant CEI

    Time frame: Up to 15 years

  4. Time to Onset of Clinically Significant CEI

    Time frame: Up to 15 years

Secondary outcomes

  1. Number of Participants With CEI and all Serious Adverse Events (SAEs)

    Time frame: Up to 15 years

  2. Duration of Disease Response Measured by Expanded Disability Status Scale (EDSS) Scores

    The EDSS is a standardized tool used to measure disability in participants with multiple sclerosis (MS). The EDSS scores range from 0 to 10, based on the severity of disability. Higher score indicates severity of disability.

    Time frame: Up to 15 years

  3. Duration of Disease Response Measured by Number of MS Relapses

    Time frame: Up to 15 years

  4. Duration of Disease Response Based on Number of T2 Lesions and Gd-enhancing T1 Lesions

    Time frame: Up to 15 years

07

Study locations

1 of 1 sites recruiting
  • TG Therapeutics Investigational Trial Site
    Morrisville, North Carolina 27560, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2027; primary completion for Dec 2039, 151 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 11, 2026
StartEst.
May 1, 2027
Primary completionEst.
Dec 1, 2039
CompletionEst.
Dec 1, 2039
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
1 site added — first site in United States
Show site
  • TG Therapeutics Investigational Trial Site · Morrisville, United States
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • TG Therapeutics Investigational Trial Site · Morrisville, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07577583
Responsible party
Sponsor
First posted
May 11, 2026
Start date
May 1, 2027 (estimated)
Primary completion
Dec 1, 2039 (estimated)
Completion
Dec 1, 2039 (estimated)
Last update
Oct 29, 2026

Study contacts

TG Therapeutics Clinical Support Team
Contact
clinicalsupport@tgtxinc.com
1-877-575-8489

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion